283 related articles for article (PubMed ID: 32468356)
1. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.
Cohen BE; Manga P; Lin K; Elbuluk N
Am J Clin Dermatol; 2020 Oct; 21(5):669-680. PubMed ID: 32468356
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PD-1/PD-L1 Axis in Human Vitiligo.
Willemsen M; Melief CJM; Bekkenk MW; Luiten RM
Front Immunol; 2020; 11():579022. PubMed ID: 33240267
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Therapies for Melanoma.
Buchbinder EI
Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
[TBL] [Abstract][Full Text] [Related]
5. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
7. Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R; Torres-López E
Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
[TBL] [Abstract][Full Text] [Related]
8. Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.
Speeckaert R; van Geel N
Exp Dermatol; 2017 Jul; 26(7):630-634. PubMed ID: 27192950
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo therapy: restoring immune privilege?
Boniface K; Seneschal J; Taïeb A; Merched A
Exp Dermatol; 2017 Jul; 26(7):635-636. PubMed ID: 27314920
[TBL] [Abstract][Full Text] [Related]
10. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
11. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
Lommerts JE; Bekkenk MW; Luiten RM
Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
[No Abstract] [Full Text] [Related]
13. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
[TBL] [Abstract][Full Text] [Related]
14. The combination therapy with the cytotoxic T lymphocyte-associated antigen-4 and programmed death 1 antibody-induced asthma in a patient with advanced melanoma.
Xu W; Lian B; Cui C; Guo J
J Cancer Res Ther; 2021 Jul; 17(3):808-810. PubMed ID: 34269318
[TBL] [Abstract][Full Text] [Related]
15. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
16. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
17. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
18. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
Levine O; Devji T; Xie F
Hum Vaccin Immunother; 2017 Aug; 13(8):1765-1767. PubMed ID: 28481695
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies.
Dousset L; Boniface K; Seneschal J
G Ital Dermatol Venereol; 2019 Aug; 154(4):435-443. PubMed ID: 30650959
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]